Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma
Author:
Publisher
John Wiley & Sons, Ltd
Link
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006812.pub2/epdf/full
Reference45 articles.
1. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study;Homesley;Journal of Clinical Oncology,2007
2. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study;Sutton;Gynecologic Oncology,2000
3. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus;Wolfson;Gynecologic Oncology,2007
4. A phase II trial of amonafide in patients with mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study;Asbury;American Journal of Clinical Oncology,1998
5. Phase II Trial of Hydroxyurea, Dacarbazine (DTIC), and Etoposide (VP-16) in Mixed Mesodermal Tumors of the Uterus: A Gynecologic Oncology Group Study;Currie;Gynecologic Oncology,1996
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A personalized nomogram for predicting 3-year overall survival of patients with uterine carcinosarcoma in a tertiary care hospital in Southern Thailand;Obstetrics & Gynecology Science;2023-05-15
2. Carcinosarcoma of Uterus – A Case Report and Review of Literature;Indian Cancer Awareness Journal;2023-05-04
3. Identification of drug targets and prognosis projection for uterine carcinosarcoma based on alternative splicing events;Computers in Biology and Medicine;2023-01
4. Evaluation of chemotherapy and radiotherapy in the adjuvant management of uterine carcinosarcoma: a population-based analysis;Archives of Gynecology and Obstetrics;2022-06-16
5. Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial;Journal of Clinical Oncology;2022-03-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3